MX2015000629A - Moduladores de benzisoxasol de neurogenesis. - Google Patents
Moduladores de benzisoxasol de neurogenesis.Info
- Publication number
- MX2015000629A MX2015000629A MX2015000629A MX2015000629A MX2015000629A MX 2015000629 A MX2015000629 A MX 2015000629A MX 2015000629 A MX2015000629 A MX 2015000629A MX 2015000629 A MX2015000629 A MX 2015000629A MX 2015000629 A MX2015000629 A MX 2015000629A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- phenyl
- disorder
- compounds
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula general (I) en donde Ar1/Ar2 son fenilo o un heteroarilo de 5 o 6 elementos; R1/R2 son hidrógeno, halógeno, alquilo inferior, CF3 o alcoxi inferior; n, m son 1 o 2; o a una sal de adición ácida aceptable farmacéuticamente, a una mezcla racémica o a su enantiómero correspondiente y/o a los isómeros ópticos de los mismos, con la excepción del compuesto de 2,1-benzisoxazol, 3-(4-clorofenil)-5-(1-fenil-1H-pirazol-5-il)-. Los compuestos pueden ser usados para el tratamiento de la esquizofrenia, el trastorno de la personalidad obsesiva-compulsiva, la depresión mayor, los trastornos bipolares, los trastornos de la ansiedad, el envejecimiento normal, la epilepsia, la degeneración retinal, la lesión traumática del cerebro, la lesión de la médula espinal, el trastorno de tensión post-traumática, el trastorno del pánico, la enfermedad de Parkinson, la demencia, la enfermedad de Alzheimer, la alteración cognitiva leve, la disfunción cognitiva inducida por quimioterapia, síndrome de Down, trastornos del espectro del autismo, la pérdida de escucha, tinnitus, ataxia espinocerebelar, esclerosis lateral amiotrófica, esclerosis múltiple, enfermedad de Huntington, ataques apopléjicos, terapia de radiación, tensión crónica, abuso de drogas neuro-activas, tales como el alcohol, los opiatos, la metanfetamina, la fenciclidina y la cocaína.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12177968 | 2012-07-26 | ||
PCT/EP2013/065452 WO2014016267A1 (en) | 2012-07-26 | 2013-07-23 | Benzisoxazole modulators of neurogenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015000629A true MX2015000629A (es) | 2015-04-14 |
MX363461B MX363461B (es) | 2019-03-25 |
Family
ID=48808373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015000629A MX363461B (es) | 2012-07-26 | 2013-07-23 | Derivados de benzisoxazol como moduladores de la neurogénesis y el uso de los mismos en el tratamiento de enfermedades neurológicas y trastornos neuropsiquiátricos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US9440962B2 (es) |
EP (1) | EP2877466B1 (es) |
JP (1) | JP5917774B2 (es) |
KR (1) | KR101675240B1 (es) |
CN (1) | CN104487438B (es) |
BR (1) | BR112015001218B1 (es) |
CA (1) | CA2878435C (es) |
ES (1) | ES2592704T3 (es) |
HK (1) | HK1206357A1 (es) |
MX (1) | MX363461B (es) |
RU (1) | RU2640590C2 (es) |
WO (1) | WO2014016267A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2004000234A1 (es) * | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
AU2005295734A1 (en) * | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
US20070254913A1 (en) * | 2006-04-19 | 2007-11-01 | Dunn Robert F | Phosphodiesterase 4 inhibitors |
WO2008046072A2 (en) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
US9095572B2 (en) | 2009-01-09 | 2015-08-04 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
-
2013
- 2013-07-23 WO PCT/EP2013/065452 patent/WO2014016267A1/en active Application Filing
- 2013-07-23 KR KR1020157004575A patent/KR101675240B1/ko active IP Right Grant
- 2013-07-23 MX MX2015000629A patent/MX363461B/es unknown
- 2013-07-23 BR BR112015001218-3A patent/BR112015001218B1/pt active IP Right Grant
- 2013-07-23 EP EP13739453.2A patent/EP2877466B1/en active Active
- 2013-07-23 CA CA2878435A patent/CA2878435C/en active Active
- 2013-07-23 ES ES13739453.2T patent/ES2592704T3/es active Active
- 2013-07-23 JP JP2015523521A patent/JP5917774B2/ja active Active
- 2013-07-23 RU RU2015104100A patent/RU2640590C2/ru active
- 2013-07-23 CN CN201380039051.9A patent/CN104487438B/zh active Active
-
2015
- 2015-01-22 US US14/602,541 patent/US9440962B2/en active Active
- 2015-07-24 HK HK15107080.9A patent/HK1206357A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014016267A1 (en) | 2014-01-30 |
MX363461B (es) | 2019-03-25 |
KR101675240B1 (ko) | 2016-11-10 |
KR20150038237A (ko) | 2015-04-08 |
RU2015104100A (ru) | 2016-09-20 |
HK1206357A1 (en) | 2016-01-08 |
US20150259334A1 (en) | 2015-09-17 |
BR112015001218A2 (pt) | 2017-07-04 |
ES2592704T3 (es) | 2016-12-01 |
CA2878435C (en) | 2020-08-25 |
CN104487438B (zh) | 2016-10-19 |
JP5917774B2 (ja) | 2016-05-18 |
CA2878435A1 (en) | 2014-01-30 |
CN104487438A (zh) | 2015-04-01 |
EP2877466A1 (en) | 2015-06-03 |
JP2015522634A (ja) | 2015-08-06 |
RU2640590C2 (ru) | 2018-01-10 |
US9440962B2 (en) | 2016-09-13 |
EP2877466B1 (en) | 2016-07-06 |
BR112015001218B1 (pt) | 2022-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016008842A (es) | Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos. | |
MX2016000895A (es) | Derivados de 1,7-naftiridina. | |
MX2015015052A (es) | Derivados de isoquinolina que estimulan la neurogenesis. | |
BR112015004942A2 (pt) | benzimidazóis como agentes ativos do snc | |
AR093576A1 (es) | Derivados heterociclicos sustituidos | |
MX2015006364A (es) | 1,6-naftiridinas sustituidas. | |
MX2016008983A (es) | Peliculas termocontraibles de barrera de multicapa pvdc. | |
MX2016008536A (es) | Derivados de fluoro-naftilo. | |
PH12016500605A1 (en) | Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders | |
AR106588A1 (es) | Derivados de indolin-2-ona para el tratamiento de enfermedades del snc | |
EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
PH12019500119A1 (en) | Ethynyl derivatives | |
PH12015500059A1 (en) | Pieprazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | |
BR112015008200A2 (pt) | derivados de imidazopiridina | |
EA201692404A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
MX2015000629A (es) | Moduladores de benzisoxasol de neurogenesis. | |
MX2015013915A (es) | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. | |
MX2016001528A (es) | Derivados de indol-carboxamida. | |
TH165816B (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท | |
TH165816A (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท | |
TH167754A (th) | ไพเพอราซิโน[1,2-a]อินดอล-1-โอนและ[1,4]ไดอะซีพิโน[1,2-a]อินดอล-1-โอน |